Alzheimer’s Association International Conference (AAIC) 2024

Dr. Erez Eitan to Participate in the Alzheimer’s Association International Conference (AAIC) 2024

We are thrilled to announce that Dr. Erez Eitan, NeuroDex’s chief scientific officer (CSO), will participate in the upcoming Alzheimer’s Association International Conference (AAIC) 2024. This prestigious event, taking place from July 28 to August 1 in Philadelphia, USA, will bring together leading scientists, researchers, and healthcare professionals from around the globe to discuss the…

Biomarkers as Game-Changers in Neurodegenerative Disease Diagnostics

Biomarkers as Game-Changers in Neurodegenerative Disease Diagnostics

Imagine a future where the onset of Alzheimer’s or Parkinson’s disease could be predicted and effectively treated before symptoms even appear. Neurodegenerative diseases have long remained shrouded in a veil of uncertainty, with definitive diagnoses often coming too late to alter their devastating trajectories. Biomarkers are the beacons of hope in this landscape, potentially revolutionizing…

Promising Results from Athira Pharma's Fosgonimeton

Promising Results from Athira Pharma’s Fosgonimeton

Athira Pharma, Inc. (NASDAQ: ATHA), a leading late-stage biopharmaceutical company dedicated to pioneering small molecules that rejuvenate neurons and decelerate neurodegeneration, has unveiled compelling findings from its SHAPE Phase 2 clinical trial. This trial assessed the potential of fosgonimeton (ATH-1017) in patients grappling with Parkinson’s disease, dementia, and dementia with Lewy bodies. Fosgonimeton Fosgonimeton is a…

Parkinson's disease

Michael J. Fox Foundation Funds Research on a Potential Parkinson’s Biomarker

Introduction:  Parkinson’s disease is a progressive neurological disorder affecting millions worldwide. It is characterized by tremors, stiffness, and impaired movement, among other symptoms. Despite decades of research, there is currently no cure for Parkinson’s disease, and limited treatment options are available to patients. However, recent advances in biomarker research offer hope for earlier detection and…

NeuroDex, Inc., Announces Award from The Michael J. Fox Foundation

NeuroDex, Inc., Announces Award from The Michael J. Fox Foundation

For application titled: “Blood Test for Parkinson’s Stratification based on Neuron and Oligodendrocyte Derived Extracellular Vesicles”NATICK, MASSACHUSETTS, UNITED STATES OF AMERICA, January 26, 2023 /EINPresswire.com/ — NeuroDex, Inc.(“NeuroDex”, or the “Company”), announces that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study, “Blood Test for Parkinson’s Stratification based on Neuron…